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Abstract  
Purpose of review 
The induced pluripotent stem (iPS) cells from patient’s somatic cells could be a useful 
source for drug discovery and cell transplantation therapies. However, there are still 
several problems to be solved in terms of safety concerns. We herein summarize the 
current knowledge about iPS cells and the obstacles that must be overcome before the 
cells can be used for medical applications. 
 
Recent findings 
Recent progress has enabled us to generate integration-free iPS cells from non-invasive 
tissues. However, several studies have also uncovered differences in iPS cells and ES 
cells in terms of gene expression, epigenetic modification, and differentiation potentials. 
Tissue origin affects the quality of iPS cells. However, in a rodent disease model, the 
transplantation of differentiated cells derived from iPS cells ameliorated their symptoms. 
Methods for gene correction and direct cell fate switching have also been reported. The 
successful generation of HLA-typed iPS cells has been described. These findings should 
therefore facilitate the further application of iPS cells. 
 
Summary 
Human iPS cells are able to provide functional neuronal cells, blood cells, and retinal 
cells, which would be a useful source for transplantation. Although recent reports have 
shown that it may be possible to overcome several difficulties associated with iPS cells, 
further improvements are needed, not only regarding safety aspects, but also in quality, 
before they can be medically applied.
Introduction 
Reprogramming of somatic cells into pluripotent stem cells has been reported 
by introducing a combination of several transcription factors (Oct3/4, Sox2, Klf4, and 
c-Myc)(1). The induced pluripotent stem (iPS) cells from patient’s somatic cells could 
provide a useful source of cells for drug discovery and cell transplantation therapies. 
However, most human iPS cells have been made using viral vectors, such as 
retroviruses and lentiviruses, which integrate the reprogramming factors into the host 
genomes and may increase the risk of tumor formation (2). To overcome the safety 
concerns about iPS cell generation, several non-integration methods have been reported, 
such as transient expression of the reprogramming factors using adenoviral vectors or 
plasmids, and direct delivery of reprogramming proteins and RNAs (3-6). These 
approaches could decrease the risk of genomic alteration, however, recent studies raised 
other obstacles in the way of future medical applications.  
Human iPS cells are able to generate neuronal cells, blood cells, and retinal 
cells (7-9). However, there have been some reports that human iPS cells show 
attenuated differentiation potential into neuronal or hematopoietic lineages in 
comparison to ES cells (10, 11). These studies indicate the limited applications of 
human iPS cells and suggest the need for improvement of reprogramming, not only in 
terms of safety, but also in quality. We herein summarize the current knowledge and 
problems associated with the development of iPS cells for medical applications. 
 
Development of an efficient non-integrated method and derivation of iPS cells 
from non-invasive tissues 
The first iPS cells were established by delivery of transgenes, Oct3/4, Sox2, Klf4, and 
c-Myc, by MMLV (Moloney Murine Leukemia Virus)-based retroviral vectors (1). 
Retroviruses can robustly infect fibroblasts and introduce their RNA genome into the 
host genome by reverse transcriptase. The resulting iPS cells had several genomic 
integrations of the transgenes. This enables effective reprogramming of somatic cells, 
however, the integrated sequences alter the genomic organization of iPS cells and can 
induce some abnormalities (12). One of the reprogramming factors, c-Myc, is a 
well-known proto-oncogene, and its reactivation could give rise to transgene 
derived-tumor formation (2). Because of these concerns, several improvements in the 
transduction methods have been studied for making non-integrated iPS cells. Generation 
of non-integrated iPS cells was first reported in mice using an adenoviral vector and by 
using a plasmid vector (3, 4), and then it was demonstrated that it was possible using 
human cells and viral vectors (adenovirus), DNA vectors (PiggyBac vector, episomal 
plasmid, and minicircle vector), and direct protein delivery (13-18). Although these 
methods can avoid genomic alterations, most of them are highly inefficient and largely 
impractical. Recent progress was made by the employment of the non-transmissible 
Sendai virus vector for reprogramming (19). The Sendai virus is a minus-strand RNA 
virus and does not have the risk of integrating into the host genome. Fusaki et al. mixed 
4 different Sendai viral vectors encoding different reprogramming factors, and 
transfected them into human fibroblasts. The viral vectors could constitutively replicate 
their RNA genome in the cytoplasm of the infected cells, to give a high reprogramming 
efficiency of up to 1%. The established iPS cells still contained viral RNA, however, the 
RNA were diluted and disappeared during cell growth. This elimination can be 
enhanced by using temperature-sensitive mutants and by antibody-mediated negative 
selection utilizing viral antigens expressed on the cell surface.  
 Direct delivery of synthetic mRNA encoding reprogramming factors also 
induced iPS cell generation at high efficiency (6). To suppress the activation of the 
cellular antiviral response, mRNAs were synthesized with modified residues of 
5-methylcytidine triphosphate and pseudouridine triphosphate. In addition, a 5’ guanine 
cap was incorporated by inclusion of a synthetic cap analog to increase the RNA 
half-life in the cytoplasm. After purification, the RNAs were mixed and transfected into 
human fibroblasts. This method provided rapid and large-scale generation of iPS cells. 
The estimated efficiency was beyond 4% when using a 5 factor cocktail (Oct3/4, Sox2, 
Klf4, c-Myc, and LIN28) and low oxygen conditions. The efficiency greatly surpassed 
that of all other reported protocols. The RNA-driven iPS cells showed pluripotency in 
their differentiation into cell types of all three germ layers. The method can also be 
applied to facilitate cell differentiation. Synthetic RNA encoding a myogenic factor, 
MYOD, enhanced the terminal differentiation of iPS cells into myotubes. 
 Many additional reprogramming factors have been reported that seem to affect 
both the induction efficiency and characteristics of iPS cells. For example, Hanna and 
colleagues found that some reprogramming factors, such as Lin28 and shRNA for p53, 
mainly regulate the reprogramming efficiency through the control of cell proliferation 
(20). In contrast, Nanog seems to enhance the efficiency of reprogramming by affecting 
the reprogramming process itself. Tbx3 was reported to improve the quality of mouse 
iPS cells, as it facilitated the germline transmission efficiency (21). Modification of cell 
signaling (by Wnt, inhibition of TGFbeta, and inhibition of MEK), or treatment with 
chemicals/natural compounds (valproic acid, 5´-azacytidine, thiazovivin, and vitamin C) 
have also been employed to develop better iPS cells (22-26). One company in the US 
has applied for a patent based on a process that generates iPS cells by using small 
molecules. Although more detailed analyses are needed, one of these approaches could 
potentially be ideal for the future generation of iPS cells.  
The origin of the iPS cells seems to be important, especially for humans. It is 
necessary to consider clinically available sources with respect to minimizing the 
invasiveness of collection and making them more easily accessible. Initially, iPS cells 
were established from fibroblasts (27, 28). Thereafter, numerous tissues sources have 
been investigated, and iPS cells can now be established from various tissues including 
keratinocytes, mesenchymal cells in fat, oral mucosa, molar teeth, peripheral blood, and 
cord blood (29-34). The generation of iPS cells from hematopoietic cells is noteworthy, 
because there are many established blood banks which already determine the HLA types 
of their blood. Seki et al. reported efficient generation of iPS cells from peripheral blood 
using Sendai viral vectors (35). 
 
Genetic correction 
iPS cells established from individual patients can provide a promising cell source for 
cell therapy, as they do not elicit immune rejection. However, when the patient suffers 
from a genetic disease, the cells need genetic correction. In general, human pluripotent 
stem cells are more difficult to modify compared to mouse ES cells. However, recent 
studies have demonstrated effective gene modification of human pluripotent cells. 
Hockemeyer et al. employed a zinc-finger nuclease (ZFN) for genome editing (36). 
They designed a ZFN that recognized adjacent genomic sequences of the correction 
locus, by fusing the FokI nuclease domain on a DNA recognition domain composed of 
engineered C2H2 zinc-finger motifs. After transduction into iPS cells, the chimeric 
proteins bind at flanking genomic regions, dimerize with the nuclease domains, and cut 
the genomic DNA. Then a donor DNA, which is homologous to the target, is 
incorporated by homology-directed repair. This approach has several limitations, 
however, it can supply a powerful tool for gene correction.  
Another method for efficient genetic correction is to use human iPS cells which 
show mouse ES cell-like characteristics. Conventional mouse and human ES cells share 
many characteristics, such as unlimited proliferation and differentiation potential into 
cells of all three germ layers, however, the cells have a significant number of distinct 
features including morphology, gene expression pattern, and cytokine dependence. 
Therefore, mouse and human pluripotent cells are termed “naïve” and “primed” 
pluripotent cells, respectively. Naïve mouse ES cells form compacted dome-shaped 
colonies in culture. They are largely dependent on external LIF signaling and have a 
high proliferation rate. On the other hand, human-type primed ES cells grow as flat 
colonies, and are predominantly dependent on bFGF signaling, and have slow growth. 
Although both types of stem cells can differentiate into cell types from all three germ 
layers, the mouse naïve stem cells seem to have higher pluripotency, which enables 
them to contribute to chimera formation and germ cell lineage. Recently, the generation 
of human naïve ES and iPS cells has been reported in the presence of LIF and chemical 
supplementation (37, 38). In contrast to primed ES cells, the human naïve ES cells 
showed similar properties as mouse naïve ES cells with regard to their morphology, 
gene expression profile, and signaling pathway dependence. Interestingly, the human 
naïve ES cells also allowed efficient gene targeting by conventional homologous 
recombination methods, similar to the mouse naïve ES cells, which could provide a 
powerful method for gene repair. However, the culture conditions for naïve human 
pluripotent cells still needs to be optimized, as they easily revert to their primed state. 
Further studies will be necessary to enable stable handling of naïve human ES cells. 
 
HLA banking 
It is estimated that it would take at least a few years to establish clinical grade cells from 
a patient’s own somatic cells. Each of the derived cell lines should be assessed for their 
medical stability, safety and efficacy. Thus, while ES cells might represent a novel 
treatment approach for currently incurable diseases, it is necessary to consider the 
applications of iPS cells from an economical view point. Complete tailor-made iPS cell 
therapy would cost too much for most people. From this point of view, a banking 
system for iPS cells is proposed. To decrease immune rejection, iPS with various HLA 
haplotypes should be collected, similar to the way whole blood is currently banked. 
Based on the experiences with organ transplantation, it appears that the most important 
HLA molecules to match are the HLA class I molecules, HLA-A and HLA-B, and the 
class II molecule, HLA-DR. HLA matching of these loci can reduce the incidence of 
acute rejection, and has improved transplant survival. Estimations of the necessary stem 
cell bank size have been calculated for the Japanese and the UK populations (39, 40). If 
170 lines of iPS cells were randomly established, 80% of such patients would be able to 
find a donor line with a single mismatch at one of the three HLA loci, HLA-A, -B, and 
–DR, with a better match found within the Japanese population. A bank size of 150 lines 
could therefore provide an acceptable match for 84.9% of the UK population. 
Importantly, when iPS cells are established from HLA homozygous cells, a smaller bank 
size of only 50 lines is expected to provide a three-locus match for 90.7% of the 
Japanese population (41). To identify at least one homozygote for each of the 50 
different HLA haplotypes, it would be necessary to examine an HLA-type database of 
24,000 individuals. This would be possible if the iPS bank cooperated with other banks, 
like cord blood banks and bone marrow banks. Generation of iPS cells from HLA-typed 
cells has already reported, thus supporting the feasibility of such a project. Tamaoki et al. 
focused on dental pulp cells, as they are easily obtained from extracted teeth, and such 
cells are generally considered to be medical waste, and can be expanded under simple 
culture conditions (42). Determination of their HLA types revealed that 2 out of 107 
lines of dental pulp cells were homozygous for HLA-A, B, and DR loci. 
 
Epigenetic memory of the source tissue 
The origin of iPS cells affects their characteristics, including their safety and their 
differentiation efficiency. Miura et al. differentiated several mouse iPS cell lines into 
neural precursor cells in vitro and evaluated their safety by transplantation into 
immunodeficient mice (43). The iPS cells they used were derived from various tissues, 
such as embryonic fibroblasts, adult tail fibroblasts, liver, and stomach. Although iPS 
cells from embryonic fibroblasts and liver tissue efficiently differentiated into neural 
lineage cells, iPS cells from tail fibroblasts remained significantly undifferentiated after 
being treated using the same differentiation protocol, which resulted in teratoma 
formation after transplantation. Interestingly, the tumorigenicity was largely associated 
with their origin, but not with inclusion of the c-Myc transgene. When a less 
tumorigenic iPS cell line was selected, the differentiated neural precursor cells could 
ameliorate the symptoms of spinal cord injury in a mouse model (44). Kim et al. also 
reported the effects of cell origin on the differentiation potential of iPS cells (45). In 
their study, iPS cells that originated from blood cells could easily differentiate into the 
hematopoietic linage, whereas iPS cells from a neuronal or fibroblast lineage showed 
limited differentiation potential. As treatment with inhibitors of DNA methyltransferase 
(5’-azacytidine) and histone deacetylase (trichostatin A) improved the hematopoietic 
differentiation capacity of iPS cells of neural origin, the epigenetic status appears to  
be important for the memory of iPS cells. In fact, several differentially methylated DNA 
regions (DMR) have been reported (46-48). Studies of the relationship between DMR 
and differentiation potential are therefore needed to determine the characteristics of iPS 
cells before inducing their differentiation. Some scientists believe that human naïve 
ES/iPS cells have less diversity than primed cells, as they are much closer to the actual 
pluripotent state and would therefore acquire full reprogramming more easily.  
 
Direct conversion 
The generation of iPS cells has clearly shown that forced expression of a few master 
regulators can modify cell fate. With this in mind, several studies have been reported 
showing the direct conversion from one somatic cell type into another cell type without 
the use of stem cells. The generation of neuron-like cells from mouse fibroblasts was 
accomplished by transduction of several transcription factors including Ascl1, Brn2, and 
Myt1l (49). The induced neuronal cells expressed multiple neuron-specific proteins, 
generated action potentials, and formed functional synapses. Ieda et al. demonstrated 
derivation of cardiomyocyte-like cells from cardiac or dermal fibroblasts by 
transduction of three developmental transcription factors, Gata4, Mef2c, and Tbx5 (50). 
The cells termed “induced cardiomyocyte-like cells” expressed cardiac-specific markers, 
had a global gene expression profile similar to cardiomyocytes, and contracted 
spontaneously. The authors also transplanted fibroblasts into immunosuppressed mouse 
hearts after gene transduction and noted the formation of sarcomeric structures within 2 
weeks. This approach represents one possible way to achieve transplantation. On the 
other hand, Zhou et al. reported direct in vivo induction of pancreatic exocrine cells to 
beta cells by transduction of three transcription factors, Ngn3, Pdx1, and Mafa (51). 
Adenoviral vectors encoding these genes were used for delivery to the pancreas of 
immunodeficient mice. The converted cells were capable of secreting insulin, and 
ameliorated hyperglycemia in streptozotocin-treated diabetic mice. As was observed for 
iPS cells, these converted cells would have some epigenetic memory of their origin. 
Further studies are required, especially investigations regarding safety, before these 
approaches can be concluded to provide an alternative method for generating specific 
differentiated cells for use in medical treatment. 
 
Conclusion 
Artificial stem cells, iPS cells, are established by the modification of the intracellular 
and extracellular environments. The iPS cells seem to have pluripotency, as mouse and 
rat iPS cells can produce chimeric animals. A tetraploid complementation experiment 
revealed that mouse iPS cells have the ability to develop into a full-term mouse 
autonomously (52, 53). These data indicate that differentiated cells derived from iPS 
cells can at least partially replace the biological functions of various cells types. Several 
therapeutic attempts have been reported in rodent models, such as treatment of 
humanized sickle cell anemia, Parkinson’s disease, and spinal cord injury (44, 54, 55). 
Although many problems still remain to be resolved, iPS cells may be applicable for 
medical treatment in the relatively near future. Studies of disease pathogenesis and drug 
discovery have already been launched, and the results thereof could provide important 
relief to countless people throughout the world who are currently suffering from 
incurable diseases or injuries.  
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